Collegium Pharmaceutical launches $150 million stock repurchase program

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) disclosed in an 8-K filed on July 1, 2025 that its Board authorized a new share repurchase program of up to $150 million of common stock, effective immediately and running through December 31, 2026.

The company intends to execute buybacks on the open market at management’s discretion, considering prevailing market conditions and share price. Funding will come exclusively from existing cash on hand; no additional debt or equity issuance is mentioned. The filing contains no earnings figures, operational updates, or changes to prior guidance.

While the authorization does not obligate the company to repurchase the full amount, the program could reduce the share count, provide support for the stock price, and signal management’s confidence in long-term prospects. Investors should note that the timing, pace, and ultimate utilization of the $150 million limit remain subject to market dynamics and internal capital allocation priorities.

Positive

• $150 million buyback authorization signals management confidence and commitment to shareholder returns
• Program is fully cash-funded, avoiding additional leverage and interest expense
• Potential to reduce share count and boost EPS if fully executed
• Two-year window (through 12/31/2026) offers flexibility to repurchase shares opportunistically

Negative

• Buyback remains discretionary; impact depends on actual shares repurchased
• Allocation of cash to repurchases may limit investment in growth initiatives or R&D
• No disclosure of current cash balance or projected liquidity post-repurchase

Insights

Equity Research Analyst

TL;DR: $150 M buyback is shareholder-friendly, modestly accretive, funded by cash; execution pace uncertain.

The $150 million authorization represents roughly 9-10% of COLL’s current market capitalization (based solely on filing data indicating no additional metrics). A cash-funded program reduces dilution risk and can lift EPS if fully executed. It also indicates the Board believes shares are undervalued relative to intrinsic value. However, because repurchases are discretionary, actual impact depends on management’s follow-through and prevailing liquidity. The lack of accompanying operational metrics leaves open questions about alternative uses of capital, but the program is directionally positive for near-term shareholder returns.

Corporate Finance Specialist

TL;DR: Buyback improves capital return profile; opportunity cost and timing risks persist.

Funding the authorization with on-hand cash suggests strong liquidity and avoids leverage. The two-year window provides flexibility, yet also dilutes immediacy of per-share benefits. Investors should monitor quarterly cash balances and actual shares retired to gauge effectiveness. Absent disclosure of growth projects, this move may imply limited higher-ROI alternatives, a potential negative if pipeline investment is required for long-term growth. Overall, the initiative skews positive but warrants tracking of execution metrics.

false 0001267565 0001267565 2025-07-01 2025-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1, 2025

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Virginia		001-37372		03-0416362
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(IRS Employer Identification No.)

100 Technology Center Drive

Suite 300

Stoughton, MA 02072

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 713-3699

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	COLL	The NASDAQ Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 8.01 Other Information.

On July 1, 2025, the Board of Directors of Collegium Pharmaceutical, Inc. (the “Company”) authorized a new share repurchase program to repurchase up to $150 million of the Company’s shares of common stock through December 31, 2026. The timing and amount of any shares purchased on the open market will be determined based on the Company’s evaluation of the market conditions, share price and other factors. The Company plans to utilize existing cash on hand to fund the share repurchase program.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 7, 2025	Collegium Pharmaceutical, Inc.
	By:	/s/ Colleen Tupper
		Name: Colleen Tupper
		Title: Executive Vice President and Chief Financial Officer

FAQ

How much stock can Collegium Pharmaceutical (COLL) repurchase?

The Board authorized up to $150 million in common stock repurchases.

What is the time frame for COLL's new share repurchase program?

Repurchases may be made from July 1, 2025 through December 31, 2026.

How will Collegium fund the share buybacks?

The company plans to use existing cash on hand; no debt financing was mentioned.

Is Collegium obligated to repurchase the full $150 million?

No. The program is discretionary; the company may repurchase any amount up to the authorized limit.

What factors will determine the timing of COLL's buybacks?

Management will consider market conditions, share price, and other factors before executing trades.